Vimarsana
Biggest News Aggregation in the World

Head Private Equity News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Head Private Equity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Head Private Equity Today - Breaking & Trending Today

Kemiex AG: Kemiex joined by strategic investors to accelerate digital trade and analytics of raw materials, chemicals - Vimarsana News

Kemiex AG: Kemiex joined by strategic investors to accelerate digital trade and analytics of raw materials, chemicals

Kemiex has secured equity investments from the strategic investment arm of CME Group, CME Ventures, the global data and analytics company DTN, as well as the family office Wille Finance. Investors

Kemiex joined by strategic investors to accelerate digital trade and analytics of raw materials, chemicals - Vimarsana News

Kemiex joined by strategic investors to accelerate digital trade and analytics of raw materials, chemicals

Kemiex has secured equity investments from the strategic investment arm of CME Group, CME Ventures, the global data and analytics company DTN, as well as the...

Kemiex Raises Funding - Vimarsana News

Kemiex Raises Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Investcorp-linked Xpressbees now a unicorn - Vimarsana News

Investcorp-linked Xpressbees now a unicorn

Investcorp, a leading global alternative investment firm, announced that its portfolio company, Xpressbees, a leading e-commerce logistics platform in India, became a unicorn after recently raising $300 million.

Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing - Vimarsana News

Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing

WAEDENSWIL, Switzerland--(BUSINESS WIRE)--May 20, 2021-- Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, today announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing. The financing was co-led by new investors Novo Holdings and HBM Partners, with participation from additional new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., funds and accounts under the ma...